02142 HBM HOLDINGS-B
- 1.400
- -0.020-1.41%
HBM HOLDINGS-B News
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Hebo Pharmaceutical-B (02142) cancelled 1.75 million shares on April 30
Hebo Pharmaceutical-B (02142) announced that 1.75 million repurchased shares will be cancelled on April 30, 2024.
和鉑醫藥-B：2023年年報
Hebo Pharmaceutical-B (02142.HK) issued 98,000 shares under the share award scheme on April 18
Hebo Pharmaceutical-B (02142.HK) issued an announcement to issue 98,000 shares on April 18, 2024 in accordance with the initial public offering after-sales share incentive plan adopted and approved by the company's shareholders on November 23, 2020.
Featured announcements | Xiaopeng and Volkswagen reached a strategic technical cooperation; Sands China's total net revenue increased 42% year over year
Anta Sports: The retail value of Anta brand products achieved a positive year-on-year increase in the number of units in the first quarter; China Building Materials expects a 147% year-on-year increase in net loss for the first quarter.
Wang Jingsong, chairman of the board of directors of Harbour BioMed (02142), promised not to reduce the company's shares for at least six months
Hebo Pharmaceutical-B (02142) announced that Dr. Wang Jinsong, Executive Director, Chief Executive Officer and Chairman of the Board of Directors, has voluntarily promised...
Hebo Pharmaceutical-B (02142.HK) grants 8.38,000 share options and 3.105 million share awards
On April 3, 2024, Gelonghui Pharmaceutical-B (02142.HK) announced that on April 3, 2024, according to the share option plan and share award plan separately adopted by the company's shareholders on November 23, 2020, the company granted 8.310,000 share options and 3.105 million share awards to eligible participants, subject to acceptance by the grantor.
HBM Holdings Returns to Profitability in 2023
HBM Holdings (HKG:2142) recorded a profit of $22.8 million in 2023, as opposed to a loss of $137.3 million in the previous year, according to a March. 28 filing with the Hong Kong bourse. Basic earnin
Profit-driven value enhancement, a glimpse into the fission acceleration of Platinum Pharmaceutical-B (2142.HK)
At the National Conference this year, the government work report clearly identified “vigorously promoting the construction of a modern industrial system and accelerating the development of new quality productivity” as the top task of the government's work in 2024. Among them, the term “innovative drug” debuted and immediately sparked a buzz in the market.
Hebo Pharmaceutical reverses losses for the first time and plans to report BLA again for myasthenia gravis | Direct performance meeting
① Hebo Pharmaceuticals achieved revenue of US$89.502 million, a year-on-year increase of 119.9%, a total profit of US$22.763 million for the year, and a loss of US$137 million in the same period last year. ② Wang Jinsong revealed, “Of the revenue for the full year of 2023, close to 60 million US dollars came from Nona Biotech.”
Hebo Pharmaceutical-B (02142.HK) announced annual results: total revenue increased 119.9% year-on-year, achieving annual financial profit for the first time
On the evening of March 29 and March 28, Gelonghui announced its 2023 annual results with Platinum Pharmaceutical-B (02142.HK). As of December 31, 2023, Hebo Pharmaceutical had a total annual profit of US$22.76 million. This is also the first time that the company has achieved annual financial profit. During the reporting period, total revenue reached US$89.5 million, up 119.9% year on year (total revenue in 2022 was US$40.66 million). The company's revenue structure mainly included product licensing, research services and technology licensing. The increase in total revenue was mainly due to companies such as Pfizer, Cullinan Oncology, and Columbautech
Read the 2023 performance highlights of Heplatinum Pharmaceuticals (02142.HK) in one picture
On the evening of March 28, Hebo Pharmaceutical (02142.HK) announced the results for the year ended December 31, 2023. Let me take you to understand the specific results in a picture.
Press Release: Harbour BioMed Reports Full Year 2023 Financial Results
Harbour BioMed Reports Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, C
Heplatinum Pharmaceuticals Announces 2023 Annual Results
Suzhou, China; Cambridge, Massachusetts; and Rotterdam, the Netherlands, March 28, 2024/PRNewswire/ -- Hebo Pharmaceuticals (stock code: 02142.HK), a global biomedical company focused on the development and commercialization of innovative drugs for cancer and immune diseases, today announced its 2023 results. Dr. Wang Jinsong, founder, chairman and CEO of Hebo Pharmaceuticals, said, “2023 is our third fiscal year since our listing on the main board of the Hong Kong Stock Exchange. We have made progress in two important tasks: the first is to make Hebo Healthcare more efficient and more focused on next-generation treatment in the clinical phase
Hebo Pharmaceutical-B (02142) announced annual results. Profit attributable to shareholders of US$22.797 million turned a year-on-year loss into a profit
Hebo Pharmaceutical-B (02142) announced results for the year ended December 31, 2023, and the group obtained revenue...
HBM HOLDINGS-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2023
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Hebo Pharmaceutical-B (02142.HK) will hold a board meeting on March 28 to approve the annual results
On March 13, Gelonghui Pharmaceutical-B (02142.HK) announced that the company will hold a board meeting on March 28, 2024 to consider and approve the Group's annual results for the year ended December 31, 2023, and deal with other matters.
HBM HOLDINGS-B: DATE OF BOARD MEETING
Analysis
Price Target
No Data
